I offer expert consultancy in medicinal chemistry and anticancer drug discovery, with a specialized focus on epigenetic targets such as histone deacetylases (HDACs), particularly HDAC3-selective inhibitors. My expertise spans rational drug design, structure–activity relationship (SAR) analysis, and optimization of small molecules for improved potency, selectivity, and pharmacokinetic properties. I provide guidance on experimental design, synthesis strategies, and biological evaluation, including cytotoxicity assays and selectivity profiling in cancer versus normal cell lines. I also support researchers in interpreting data, troubleshooting experimental challenges, and developing mechanistic insights for lead compounds.

Additionally, I assist in scientific writing, manuscript preparation, and research proposal development, helping translate complex research into high-quality publications and impactful projects.